Qinghua Wang, Innogen CEO
December 23, 2021 09:57 AM ESTUpdated January 6, 10:06 AM
Financing

Inno­gen nets $120M to ad­vance Trulic­i­ty, Ozem­pic ri­val; ven­ture in­to man­u­fac­tur­ing

Paul Schloesser

Associate Editor

A low pro­file, Chi­nese biotech has been work­ing on de­vel­op­ing drugs for di­a­betes and meta­bol­ic dis­or­ders. Now, the com­pa­ny, known as Inno­gen Phar­ma­ceu­ti­cal Tech­nol­o­gy, has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times